Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).

@article{Byrd2002PretreatmentCA,
  title={Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).},
  author={John C. Byrd and Krzysztof Mr{\'o}zek and Richard K. Dodge and Andrew J. Carroll and Colin G. Edwards and Diane C. Arthur and Mark J. Pettenati and Shivanand R. Patil and Kathleen W. Rao and Michael S. Watson and Prasad Koduru and Joseph O. Moore and Richard M. Stone and Robert J. Mayer and Eric J. Feldman and Frederick R. Davey and Charles A Schiffer and Richard A. Larson and Clara Derber Bloomfield},
  journal={Blood},
  year={2002},
  volume={100 13},
  pages={
          4325-36
        }
}
We analyzed prospectively 1213 adults with de novo acute myeloid leukemia (AML) to ascertain the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-year overall survival (OS). All patients received similar induction therapy. Median follow-up for surviving patients was 8.3 years. Nonprioritized cytogenetics distinguished t(8;21) and inv(16)/t(16;16) as conferring a significantly better prognosis than normal… 

Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.

The data suggest that converting to normal karyotype at the time of first CR is an important prognostic indicator and support the use of CRc as a criterion of CR in AML.

Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.

  • Yiming ChenJ. Cortes F. Ravandi
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
Persistent cytogenetically abnormal cells at CR predict a significantly shorter RFS and OS, and SCT in CR1 may improve the clinical outcome of patients lacking cytogenetic remission after induction although this depends on patient selection.

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Pretreatment cytogenetics adds to other prognostic factors in older AML patients, and patients with complex > or = 5 appear to benefit minimally from current treatment and are better suited for investigational therapy or supportive care.

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

St stratification demonstrated that a large subgroup of patients, characterized by age 70 or older or high-risk cytogenetics, or both, had very unfavorable treatment results despite intensive chemotherapy, demonstrating that karyotype and age are major determinants of outcome in elderly patients with AML.

Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

A new prognostic model for risk stratification of AML patients with +8 is provided and the data indicate that allogeneic HSCT may prolong RFS compared to that achieved with other strategies of post-remission therapy.

Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

  • J. KrauterK. Wagner A. Ganser
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
Risk stratification of AML patients with reciprocal translocations of chromosome band 11q23 is feasible based on the translocation partner and clinical parameters.

Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials

Diagnostic karyotype provides the framework for risk-stratification schemes in acute myeloid leukemia (AML); however, the prognostic significance of many rare recurring cytogenetic abnormalities

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Analysis of outcomes of 5876 patients treated in Medical Research Council trials allows more reliable prediction of outcome for patients with rarer abnormalities and may facilitate the development of consensus in reporting of karyotypic information in clinical trials involving younger adults with AML.
...

References

SHOWING 1-10 OF 77 REFERENCES

Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

In de novo adult AML patients not receiving SCT, IT(C) appears to independently predict a poor outcome that may be improved with SCT in first remission, and Prospective studies are required to confirm this hypothesis.

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

This study suggests that hierarchical cytogenetic classification identifies biologically distinct subsets of AML that are represented in all age groups, and highlights the importance of karyotype as a critical independent determinant of outcome in older patients with AML.

Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group.

A group of 201 adult patients with de novo acute myeloid leukemia were investigated to determine the prognostic significance of karyotype on early death, drug resistance, continuous complete remission (CCR) and survival probabilities at 5 years.

Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases

The findings do not support the previously reported ‘favourable’ prognosis of t(15;17) translocations, but suggest that the prognosis associated with t(9;11) or its variants (at least in adults), and trisomy 8 might be less severe than suggested in other studies.

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

Subgroup analysis demonstrated that the three cytogenetically defined prognostic groups retained their predictive value in the context of secondary as well as de novo AML, within the pediatric age group and furthermore were found to be a key determinant of outcome from autologous or allogeneic bone marrow transplantation (BMT) in first CR.

Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.

Detailed cytogenetic analyses were performed on specimens from 198 patients with de novo acute nonlymphocytic leukemia, including high-resolution banding studies in 79 patients, suggesting patients with abnormalities associated with poor responses may be considered for investigational approaches and may provide insights into mechanisms of drug resistance.

Karyotype in acute myeloblastic leukemia: prognostic significance in a prospective study assessing bone marrow transplantation in first remission.

It is shown that the karyotype retains its prognostic value when the intentions is to treat patients with acute myeloblastic leukemia in CR1 with BMT.

Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor.

The authors analyzed 51 cases of acute myeloid leukemia carrying a translocation t(8;21)(q22;q22); 23 female and 28 male patients and found the loss of a sex chromosome had no influence on prognosis, but a partial deletion of the long arm of chromosome 9 was an unfavorable prognostic factor.

Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients

In conclusion, complex chromosome aberrations in de novo AML predicted a dismal outcome, even when patients were treated with intensive chemotherapy, and patients under the age of 60’years with complex aberrant karyotypes may benefit from HAM treatment during induction.
...